• Clinical, Electrophysiological and Biological Diagnostic Criteria of Sensory Neuronopathies

  NCT02514109

  TerminatedObservationalUpdated Sep 20, 2016
• Prognostic Outcome Score in Functional Neurological Disorders

  NCT05003557

  CompletedObservationalUpdated Feb 28, 2023
• Nerve Ultrasound in Acquired and Genetic Sensory Neuronopathies

  NCT07365631

  Not yet recruitingObservationalUpdated Jan 26, 2026
• Diagnostic of Chemotherapy Induced Neuropathy in Children

  NCT04262778

  CompletedObservationalUpdated Nov 20, 2025
• Medico-economic and Quality of Life Impact of Sjogren-associated Small Fiber Neuropathy

  NCT03509064

  RecruitingObservationalUpdated Feb 5, 2026
• Electrochemical Skin Conductance in Evaluation of Chronic Neuropathy électrochimique cutanée

  NCT03506659

  TerminatedInterventionalNot ApplicableUpdated Feb 28, 2020

ClinicalTrials.gov ID

NCT07651540

Lead Sponsor

Centre Hospitalier Universitaire de Saint EtienneOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

70Estimated

Last Update Posted

Jul 10, 2026Actual

Start Date

Jul 6, 2026Actual

Primary Completion Date

Jun 25, 2028Estimated

Completion Date

Jun 25, 2028Estimated

Official Title

Clinical Evaluation of Sensory Neuronopathies: the Neuronoscore Study

Brief Summary

Sensory neuronopathies (SN) are a group of rare neuropathies characterized by selective destruction of sensory neurons located in the dorsal root ganglia. SN may result from a wide range of etiologies, particularly paraneoplastic, autoimmune, toxic, and genetic causes. The functional prognosis of patients with SN is generally poor: in a recent study, two-thirds of patients had a modified Rankin Scale (mRS) score ≥3 and nearly half had an mRS ≥4.

The absence of reliable biomarkers in neuropathies justifies the use of clinical scales as indicators of disease severity, disability, and treatment response. However, none of the currently available "general neuropathy" scales have been specifically designed or validated for SN. The only scale developed specifically for SN is the SEARS (Sensory Ataxia Rating Scale), proposed in 2019, but it has not been widely used nor validated in large populations.

As a result, the absence of a clinical scale specifically designed for patients with SN makes longitudinal follow-up more challenging, particularly when assessing the response to immunomodulatory or immunosuppressive treatments when these therapies are indicated.

• Sensory Neuronopathy

• Longitudinal monitoring of clinical assessment scores to identify the most appropriate tool for tracking disease progression in sensory neuronopathies.

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Patient affiliated with or beneficiary of a social security system
• Patient having received appropriate study information
• Adult patient ≥18 years old, male or female
• Patient diagnosed with probable SN according to Camdessanché et al. diagnostic criteria
• SN with one of the following etiologies:

Paraneoplastic SN with anti-Hu or anti-CV2/CRMP5 antibodies SN associated with Sjögren's syndrome, systemic lupus erythematosus, or primary biliary cholangitis Platinum-salt-induced SN SN caused by CANVAS syndrome

Exclusion Criteria:

• Patient unable to understand or read French

• Patient refusal to participate

• Patient known to have another neuropathy phenotype and/or etiology that could significantly influence clinical scales and electrophysiological parameters, including:

  • Diabetes mellitus
  • Significant alcohol consumption
  • Severe chronic kidney disease (GFR <30 ml/min)
  • Vitamin B12 and/or vitamin E deficiency
  • Vitamin B6 excess
  • Chemotherapy other than platinum salts
  • HIV infection

Primary Purpose

Other

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Centre Hospitalier Universitaire de Saint EtienneOTHER

puma.ar@chu-nice.fr+33 4 92 03 90 73